Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants
RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans. PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage IV non-small cell lung cancer and in healthy participants.
Checked against the public recordLast updated Aug 5, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Jonsson Comprehensive Cancer Center
- Interventions being studied
- Procedure: fluorine F 18 FEQA + positron emission tomography
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Must meet 1 of the following criteria: * Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy * Stage III or IV disease * Clinically assessed with * Healthy participant Exclusion Criteria:
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Jonsson Comprehensive Cancer Center at UCLALos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 5, 2020. Always confirm current availability with the study team.